Annandale Capital’s UroGen Pharma URGN Stock Holding History

Annandale Capital’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.67M	Sell	45,425 -13,127	-22%	-$356K	0.23%	64
2026 Q1	$1.05M	Sell	58,552 -2,000	-3%	-$40.1K	0.15%	72
2025 Q4	$1.42M	Sell	60,552 -10,000	-14%	-$217K	0.17%	73
2025 Q3	$1.41M	Sell	70,552 -5,000	-7%	-$89.8K	0.24%	69
2025 Q2	$1.03M	Hold	75,552	–	–	0.08%	72
2025 Q1	$836K	Hold	75,552	–	–	0.05%	83
2024 Q4	$805K	Hold	75,552	–	–	0.13%	80
2024 Q3	$960K	Hold	75,552	–	–	0.13%	79
2024 Q2	$1.27M	Sell	75,552 -6,000	-7%	-$85.3K	0.22%	69
2024 Q1	$1.22M	Sell	81,552 -279	-0.3%	-$4.56K	0.23%	70
2023 Q4	$1.23M	Hold	81,831	–	–	0.23%	76
2023 Q3	$1.15M	Sell	81,831 -2,500	-3%	-$40.1K	0.29%	62
2023 Q2	$873K	Hold	84,331	–	–	0.25%	68
2023 Q1	$779K	Hold	84,331	–	–	0.25%	65
2022 Q4	$748K	Hold	84,331	–	–	0.25%	68
2022 Q3	$702K	Hold	84,331	–	–	0.26%	70
2022 Q2	$691K	Hold	84,331	–	–	0.27%	65
2022 Q1	$735K	Sell	84,331 -1,923	-2%	-$15K	0.29%	63
2021 Q4	$820K	Hold	86,254	–	–	0.36%	61
2021 Q3	$1.45M	Hold	86,254	–	–	0.87%	28
2021 Q2	$1.32M	Hold	86,254	–	–	0.79%	31
2021 Q1	$1.68M	Hold	86,254	–	–	1.19%	23
2020 Q4	$1.55M	Buy	+86,254	New	+$1.81M	1.3%	22

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Annandale Capital's URGN Position: Q2 2026 in Review

Annandale Capital reduced its UroGen Pharma (URGN) stake by 22% in Q2 2026, selling an estimated $356K and leaving 45,425 shares worth $1.67M. The position accounts for 0.23% of the portfolio, ranked #64.

Annandale Capital first reported a position in URGN in Q4 2020 and has held it in 23 quarters since. The position peaked at $1.68M in Q1 2021. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Annandale Capital held 45,425 shares of UroGen Pharma worth $1.67M as of Q2 2026.
Annandale Capital sold 13,127 UroGen Pharma shares in Q2 2026, an estimated $356K.
UroGen Pharma made up 0.23% of Annandale Capital's portfolio in Q2 2026, its #64 holding.
Annandale Capital first reported a position in UroGen Pharma in Q4 2020 and has held it in 23 quarters since.
Annandale Capital's UroGen Pharma position peaked at $1.68M in Q1 2021.
189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Annandale Capital's 13F filing for Q2 2026, filed 13 Aug 2026.